×

Biotech and Pharmaceuticals Pharmaceuticals

  • The outside of the Food and Drug Administration headquarters is seen in White Oak, Md., on Monday, November 9, 2015.

    South Korea's Samsung Bioepis wins U.S. FDA nod for biosimilar of J&J's Remicade.

  • CNBC Mad Money Lightning Round

    Jim Cramer flies through his take on caller favorite stocks, including this struggling drugmaker.

  • The U.S. Food and Drug Administration approved Renflexis, developed by Samsung Bioepis Co. of South Korea. Its U.S. partner, Merck& Co. of Kenilworth, New Jersey, will market Renflexis. The first biosimilar for Remicade, Inflectra from New York- based Pfizer Inc., went on sale in November at a 15 percent discount.

  • The Food and Drug Administration said Friday that it approved Renflexis, developed by Samsung Bioepis Co. of South Korea. It will be marketed by its U.S. partner, Merck& Co. of Kenilworth, New Jersey. Without insurance, Remicade generally costs more than $30,000 annually for adults; dosage varies with the patient's weight.

  • A drugmaker asked Arkansas officials not to purchase its products for executions months before the state accepted a third-party "donation" of potassium chloride as one of three drugs to use in lethal injections, according to letters obtained by The Associated Press. Fresenius Kabi USA wrote to Department of Correction Director Wendy Kelley and other...

  • April 21- Canadian drugmaker Valeant Pharmaceuticals International Inc said it had priced its recently approved plaque psoriasis treatment at $3,500 per month, ahead of an expected U.S. launch in the second half of 2017.. Taltz is priced at about $6,000 per month, while Cosentyx at $5,400 per month as per the recommended dosing schedules, she said.

  • April 21- Canadian drugmaker Valeant Pharmaceuticals International Inc said it had priced its recently approved plaque psoriasis treatment at $3,500 per month, ahead of an expected U.S. launch in the second half of 2017.. Drugmakers are facing intense criticism from politicians, insurance companies and patient advocacy groups in the United States over the...

  • April 21- Embattled Canadian drugmaker Valeant Pharmaceuticals International Inc, said on Friday that it had priced its recently approved plaque psoriasis treatment at $3,500 per month. The company expects to launch the drug in the United States in the second half of 2017.. The drug secured U.S. Food and Drug Administration approval in February this year.

  • Dolin of Glencoe claimed GlaxoSmithKline failed to warn her husband's doctor of the drug's increased risk of suicidal behavior. The jury agreed with her that GlaxoSmithKline was still responsible because the drugs are identical and have the same labeling. In a statement, GlaxoSmithKline said Thursday's decision was disappointing and they plan to appeal.

  • April 20- Teva Pharmaceutical Industries Ltd launched its version of GlaxoSmithKline's asthma inhaler Advair on Thursday and, in an unusual move, also introduced the authorized generic of its own drug. Teva's branded inhaler will cost wholesalers or direct purchasers $285, while the generic version will cost $90, company spokeswoman Michelle Larkin told...

  • The FDA also said breastfeeding women shouldn't take them because of possible harm to the baby. The FDA urged parents to carefully read labels of nonprescription cough medicines to avoid codeine and to consult a doctor or pharmacist if needed. On Thursday, FDA said that some children are at higher risk of harm from the medicines because they break down codeine...

  • Bernstein analyst Erica Kazlow said the branded inhaler was priced at $285 wholesale acquisition cost, while the authorized generic was priced at $90. GSK has been preparing for the loss of Advair exclusivity for the past two years but the potential launch of generics will still be a blow, since the medicine is highly profitable and has sold more than a $1...

  • *Japan's generic market is one-tenth of U.S. market in size. TOKYO, April 20- Japan's Sawai Pharmaceutical Co Ltd is buying the generic drug business of U.S. drug maker Upsher-Smith Laboratories Inc for $1.05 billion, marking the Osaka- based generic drugmaker's first overseas acquisition. Sawai's move to diversify geographically comes amid slow growth in...

  • The decision, coming after advertisers had begun to flee his show, ends a more than 20- year career at Fox News for O'Reilly, a best-selling author as well as one of the most popular commentators on U.S. television. In an internal memo to Fox News employees seen by Reuters, Rupert Murdoch called O'Reilly "one of the most accomplished TV personalities in the history of...

  • President Donald Trump meets with representatives from PhRMA, the Pharmaceutical Research and Manufacturers of America, in the Roosevelt Room of the White House on Jan. 31, 2017, in Washington, DC.

    Discussing who is to blame for higher drug pricing with Mark Merritt, PCMA CEO; Stephen Ubl, Pharmaceutical Research and Manufacturers of America (PhRMA) president and ceo; and CNBC's Meg Tirrell.

  • The decision ends a more than 20- year career at Fox News for O'Reilly, who is a best-selling author as well as one of the most popular commentators on U.S. television. In an internal memo to Fox News employees seen by Reuters, Rupert Murdoch called O'Reilly "one of the most accomplished TV personalities in the history of cable news." Carlson's show had been moved...

  • Martin Shkreli (C), former chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals, departs following a hearing at a U.S. federal court in New York City on June 6, 2016.

    The notorious pharma bro Shkreli denies claims he looted a drug company he founded to pay off hedge fund investors he allegedly defrauded.

  • April 19- Martin Shkreli, the former drug company executive who drew public outcry when he raised the price of a life-saving drug by 5,000 percent, will be tried for securities fraud separately from a lawyer charged alongside him, a Brooklyn federal judge ruled Wednesday. Both Shkreli and lawyer Evan Greebel, who worked for Shkreli's former company Retrophin...

  • After a thorough and careful review of the allegations, the company and Bill OReilly have agreed that Bill OReilly will not be returning to the Fox News Channel, the company said in a statement. It is not known exactly how Fox News would handle O'Reilly's exit or whether he would be allowed to say goodbye to viewers on the air, according to the New York magazine...

  • NEW YORK, April 19- Fox News has decided to part ways with star host Bill O'Reilly following allegations of sexual harassment, New York magazine reported on Wednesday, citing anonymous sources briefed on the discussions. It is not known exactly how Fox News will handle O'Reilly's exit or whether he would be allowed to say goodbye to viewers on the air, according to...